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Abstract
Murine gammaherpesvirus 68 (MHV68) establishes long-term latency in memory B cells similar to the human
gammaherpesvirus Epstein Barr Virus (EBV). EBV encodes an interleukin-10 (IL-10) homolog and modulates cellular IL-10
expression; however, the role of IL-10 in the establishment and/or maintenance of chronic EBV infection remains unclear.
Notably, MHV68 does not encode an IL-10 homolog, but virus infection has been shown to result in elevated serum IL-10
levels in wild-type mice, and IL-10 deficiency results in decreased establishment of virus latency. Here we show that a
unique MHV68 latency-associated gene product, the M2 protein, is required for the elevated serum IL-10 levels observed at
2 weeks post-infection. Furthermore, M2 protein expression in primary murine B cells drives high level IL-10 expression
along with increased secretion of IL-2, IL-6, and MIP-1a. M2 expression was also shown to significantly augment LPS driven
survival and proliferation of primary murine B cells. The latter was dependent on IL-10 expression as demonstrated by the
failure of IL10
2/2 B cells to proliferate in response to M2 protein expression and rescue of M2-associated proliferation by
addition of recombinant murine IL-10. M2 protein expression in primary B cells also led to upregulated surface expression of
the high affinity IL-2 receptor (CD25) and the activation marker GL7, along with down-regulated surface expression of B220,
MHC II, and sIgD. The cells retained CD19 and sIgG expression, suggesting differentiation to a pre-plasma memory B cell
phenotype. These observations are consistent with previous analyses of M2-null MHV68 mutants that have suggested a role
for the M2 protein in expansion and differentiation of MHV68 latently infected B cells—perhaps facilitating the
establishment of virus latency in memory B cells. Thus, while the M2 protein is unique to MHV68, analysis of M2 function has
revealed an important role for IL-10 in MHV68 pathogenesis—identifying a strategy that appears to be conserved between
at least EBV and MHV68.
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Introduction
Herpesviruses establish life-long, latent infections characterized
by episodic virus reactivation and subsequent virus shedding.
Chronic infections with the lymphotropic gammaherpesviruses are
associated with a variety of lymphomas and carcinomas which in
humans includes Burkitt’s lymphoma, nasopharyngeal carcinoma,
Hodgkin’s disease and Kaposi’s sarcoma. The narrow host range
of the gammaherpesviruses that infect humans, Epstein-Barr Virus
(EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV), has
severely hindered detailed pathogenesis studies. Murine gamma-
herpesvirus 68 (MHV68; also known as cHV68 and murine
herpesvirus 4) shares extensive genetic homology and biological
similarity with both EBV and KSHV and is a natural pathogen of
wild murid rodents. As such, MHV68 infection of inbred strains of
mice has gained favor as a small animal model in which to
evaluate viral and host determinants of gammaherpesvirus
pathogenesis in vivo.
Upon intranasal infection, MHV68 infection results in acute
viremia in the lung that is later resolved into a latent infection of B
cells, dendritic cells, and macrophages [1]. B cells are necessary for
trafficking of virally infected cells to the spleen, leading to the
establishment of splenic latency [2,3]. The CD8
+ T cell response is
critical for control of lytic infection in the lung as well as
establishment of latent viral load in the spleen [4]. MHV68
infection results in a CD4
+ T cell-dependent expansion of splenic
B cells and both virus-specific and non-specific hypergammaglob-
ulinemia [5,6]. Similar to EBV pathogenesis, memory B cells are
the primary long-term reservoir of latent MHV68 in mice [7,8,9].
All herpesviruses manipulate the host’s immune system to
establish and maintain a long-term, latent infection, and many of
these immunomodulatory mechanisms are conserved among the
members of the gammaherpesvirus family. Both KSHV and
MHV68 encode proteins, K3 and mK3, respectively, that
downregulate MHC I [10]. MHV68 also encodes a viral bcl-2
homolog, a viral cyclin, and a chemokine-binding protein, M3
[11,12,13]. The EBV proteins LMP1 and LMP2a mimic CD40
and tonic BCR signals, respectively, to manipulate B cell
development and are believed to enable the virus to gain access
to the memory B cell compartment independent of antigenic
stimulation of the host B cell [14,15]. KSHV encodes both a viral
IL-6 and a viral MIP-1a ortholog, while EBV encodes a viral IL-
10 homolog, BCRF1 (or vIL-10) [16,17].
Interleukin-10 (IL-10) was first noted as a cytokine synthesis
inhibitory factor (CSIF) that is secreted by TH2 cells and
suppresses the activity of TH1 cells [18]. IL-10 enhances murine
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class switching in culture [17,19]. In addition, IL-10 suppresses
TH1 responses through modulation of macrophage function by
downregulation of MHC II and costimulatory molecules as well as
inhibition of cytokine production and macrophage effector
functions [20,21]. Dendritic cells exposed to IL-10 do not down-
regulate costimulatory molecules but do secrete lower levels of IL-
12, impairing their ability to induce a TH1 response [22].
The M2 protein, unique to MHV68, has been shown to play a
critical role in both the establishment of latency as well as
reactivation from latency [23,24,25]. A M2-null strain of MHV68
(MHV68/M2.Stop) replicates with wild-type efficiency in mice
following intranasal inoculation but exhibits a dose-dependent
defect in the establishment of latency at day 16 post-infection
[23,24]. Under conditions in which the MHV68/M2.Stop mutant
can efficiently establish a latent infection (high dose intranasal
inoculation or low dose intraperitoneal inoculation), the M2-null
virus exhibits a profound reactivation defect, revealing dual roles
for the M2 protein in the viral life-cycle [23,24]. Additionally,
efficient transition of latently-infected B cells from the germinal
center reaction to the memory B cell reservoir appears to be stalled
in the absence of M2, suggesting M2 may manipulate B cell
signaling or differentiation to facilitate establishment of long-term
latency in the memory B cell pool [24,26]. Numerous candidate
SH3 binding motifs throughout M2 suggest the protein may
function as a molecular scaffold that may modulate specific
cellular signal transduction pathways. Consistent with this
hypothesis, M2 has been shown to interact with a number of
cellular proteins in vitro. M2 co-immunoprecipitates with Vav1 in
S11 B cells, a MHV68 latently infected cell line, and M2 and Vav1
overexpression in A20 B cells leads to Vav1 phosphorylation,
trimerization with Fyn, and downstream activation of Rac1 [27].
In fibroblast cultures, M2 interacts with DDB1/COP9/cullin
repair complex and ATM to suppress DNA-damage induced
apoptosis [28]. In addition, M2 can suppress STAT1/2 expres-
sion, leading to inhibition of the interferon response [29].
However, to date the impact of M2 expression in primary murine
B cells has not been reported.
Here we show that one function of the M2 protein is to induce
expression of IL-10 in primary B cells, demonstrating a common
immunomodulatory strategy utilized by those gammaherpes-
viruses encoding a viral IL-10 homolog and MHV68.
Results
MH68 M2 protein augments LPS-driven B cell
proliferation
The MHV68 M2 protein has been shown to be critical for
both establishment and reactivation from B cell latency. M2 has
no known homologous proteins, viral or cellular, and contains
numerous SH3 binding motifs through which it can potentially
manipulate B cell biology. Proliferating B cells harbor the
majority of latent MHV68 genomes, and splenic B cell activation
is associated with MHV68 infection at the onset of latency
[30,31]. We asked whether expression of M2 in primary murine
B cells in vitro altered proliferation or activation. B cells were
purified by negative selection from mouse splenocytes, stimulated
overnight with LPS, and transduced with either an M2 protein
expressing recombinant murine stem cell virus (MSCV) retrovi-
rus, MSCV-M2-IRES-Thy1.1, or a control retrovirus, MSCV-
M2.Stop-IRES-Thy1.1, which harbors a translation termination
codon near the 59 end of the M2 open reading frame at amino
acid 13 (Figure 1A). LPS stimulation is necessary for efficient
retroviral transduction in this system because MSCV infection
requires the cells to be in cycle [32]. The presence of an IRES-
Thy1.1 cassette readily allowed retroviral transduction efficiency
to be monitored by flow cytometry for surface expression of
Thy1.1. Notably, expression of the M2 protein from the retroviral
construct could be detected as demonstrated by immunoprecip-
itation and immunoblotting of whole cell lysates harvested from
primary B cells transduced with MSCV-M2-IRES-Thy1.1 at four
days post-transduction (Figure 1B). It should be noted that
detection of M2 expression in the transduced primary murine B
cells required immunoprecipitation with a chicken anti-M2
antisera raised against two M2 peptides, followed by immuno-
blotting with a rabbit polyclonal antiserum raised against a
bacterially expression recombinant M2 protein. In contrast, M2
expression in the MHV68 latently infected B lymphoma cell line
S11 can be detected by immunoblotting S11 lysates with the
rabbit polyclonal anti-M2 antiserum (data not shown). Thus, it
does not appear that M2 is ‘‘over-expressed’’ in transduced
primary murine B cells.
Two days post-transduction, there were similar frequencies of
transduced, Thy1.1
+ B cells in the control and M2-transduced B
cell cultures. However, by 5–6 days post-transduction, nearly
100% of the B cell culture transduced with MSCV-M2-IRES-
Thy1.1 was Thy1.1
+ as compared to ca. 20% of the culture
transduced with the control vector, MSCV-M2.Stop-IRES-
Thy1.1 (Figure 1C). Notably, the dominance of M2-expressing,
Thy1.1
+ B cells in the M2-transduced cultures was observed
repeatedly. The increase in the percentage of Thy1.1
+ cells in the
M2-transduced culture was gradual, and it did not correspond to
an increase in overall cell number in the cultures or a decrease in
cell death (Figure 1D). The latter result suggests that in a mixed
culture (M2 expressing and non-expressing cells), the non-
transduced primary B cells are actively selected against. This
could either be due to the secretion of a ‘‘toxic’’ factor by the M2
expressing cells or competition for a limiting factor necessary for
cell survival.
Author Summary
Gammaherpesviruses are able to maintain life-long,
quiescent infections (latency) in lymphocytes characterized
by intermittent production of infectious progeny virus
(reactivation). The murine gammaherpesvirus 68 (MHV68)
has extensive genetic and phenotypic similarities to the
human gammaherpesviruses Epstein-Barr virus (EBV) and
Kaposi’s sarcoma associated herpesvirus (KSHV). Similar to
EBV pathogenesis, MHV68 establishes long-term latency in
memory B cells. A unique MHV68 protein designated M2 is
known to play an important role in both establishment of
latency and reactivation from latency. Efficient transition of
MHV68 latency to the memory B cell population is
hindered in the absence of M2, leading to the hypothesis
that M2 may be involved in MHV68-driven B cell
differentiation. In this study we show that M2 expression
enhanced primary murine B cell survival, proliferation, and
differentiation in culture. M2 expressing B cells secreted of
high levels of IL-10 that is necessary for the observed
expansion of the M2-expressing B cell population in vitro.
Mice infected with a M2-null MHV68 mutant had a
significant decrease in serum IL-10, and this correlated
with an increased frequency of MHV68-specific CD8
+ T
cells in these animals. Thus, M2 manipulation of IL-10
signaling appears to both drive expansion of the major
latency reservoir (B cells), as well as dampen the immune
response to the virus facilitating both viral latency and
reactivation.
MHV68 Modulation of IL-10 Expression
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culture, we asked whether M2 was influencing B cell survival,
proliferation, or both. To directly assess B cell survival in M2-
transduced and control retrovirus cultures (M2.Stop), cells were
stained with anti-Thy1.1, Annexin V, and 7-AAD and analyzed by
flow cytometry. In contrast to the results obtained by trypan blue
exclusion which measured the live/dead ratio in the entire culture
(Figure 1D), flow cytometry of the transduced and untransduced
populations within the culture revealed a survival advantage of the
M2-transduced B cells. At day 2 post-transduction, 20% more of
the M2-transduced B cells were alive (AnnexinV
2 7-AAD
2) than
the untransduced cells in the same culture (Figure 2B). At day 3
post-transduction, there was a four-fold higher frequency of live
cells in the M2-transduced population as compared to the
untransduced cells in culture (Figure 2, panels A & B). M2-
transduced cells continued to survive better than the untransduced
cells in the population, despite an equal frequency of cells entering
apoptosis (data not shown).
At day 2 post-transduction, the M2-transduced cells have equal
frequencies of live cells as the control M2.Stop retrovirus
transduced cells (Figure 2B). Analysis at day 3 post-transduction
revealed a 20% increase in the frequency of live cells in the M2-
transduced population as compared to the cells transduced with
the control retrovirus (Figure 2B). This trend continued until the
end of the time-course, with a higher frequency of live cells found
in the M2-transduced population versus the M2.Stop retrovirus
control (Figure 2B). The increased frequency of live cells in the
M2-transduced population versus both the untransduced cells
within the culture as well as the control retrovirus transduced
population reveals a pro-survival effect of M2 protein expression in
B cells.
We next addressed whether M2 protein expression altered
proliferation in the B cell cultures thereby contributing to the
expansion of transduced cells. To directly assess B cell
proliferation in M2-transduced and control retrovirus cultures,
cells were pulsed with bromodeoxyuradine (BrdU) for 24 hours at
different time points post-transduction. Cells were surface stained
for Thy1.1 and proliferation was measured by intracellular
staining for incorporation of BrdU. The time course analyses
revealed that B cells transduced with either the M2 or control
retrovirus exhibited equivalent frequencies (84–90%) of prolifer-
ating cells 2 days post-transduction (Figure 2D). However, 80–
90% of M2-transduced B cells continued to proliferate 3 and 4
days post-transduction as compared to 40–50% of the cells
transduced with the control retrovirus (Figures 2, panel C & D).
By 5–6 days post-transduction there was a significant drop in the
proliferation of M2-transduced B cells (Figure 2D). These results
indicate that M2 protein expression is able to transiently augment
murine B cell proliferation. Thus, these analyses indicated that
the M2 protein contributes to both enhanced B cell survival as
well as promoting continued B cell proliferation post-LPS
stimulation – which together leads to dominance of M2-
transduced B cells in the primary murine B cell cultures over
the time-course analyzed.
M2 protein expression leads to B cell differentiation
The transition from the germinal center B cell population to the
long-lived memory B cell compartment is critical for establishment
of MHV68 latency [8,9]. Latent genomes in mice infected with
M2-deficent MHV68 accumulate in the germinal center com-
partment late in infection, leading to the hypothesis that M2 is
capable of manipulating B cell differentiation [26]. To determine
Figure 1. M2 expression in primary B cells leads to expansion of the tranduced population. (A) The M2 open reading frame and M2 ORF
with a stop codon at amino acid number 13 (M2.Stop) were cloned into the MSCV-IRES-Thy1.1 vector. (B) Expression of M2 protein in primary murine
B cells four days post-transduction. B cells were lysed in CHAPS-BOG and immunoprecipitated with chicken anti-M2 IgY and blotted with rabbit anti-
M2 antisera. (C) M2-transduced B cells expand in culture over time. B cells were purified by negative selection MACS separation, and B cell cultures
were between 94–97% pure (gated on CD19
+). Triplicate B cell cultures were transduced with M2 or M2.Stop retroviruses and allowed to rest for
48 hours before analysis. Cells were stained with anti-Thy1.1 and analyzed daily for expression. Data representative of more than three independent
experiments. (D) Absolute numbers of cells per well are unchanged over time. Trypan exclusion was used to count absolute numbers of live and
dead cells in triplicate wells per day. Data representative of at least two independent experiments.
doi:10.1371/journal.ppat.1000039.g001
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expression of B cell differentiation markers was analyzed by flow
cytometry. At four days post-transduction, B cells expressing M2
were CD19
+, CD25
high, GL7
high, B220
low, I-A
bl o w , surface IgD
2
(sIgD), sIgG
+, and CD138
low when compared to untransduced
cells within the culture (Figure 3A). Strikingly, M2-transduced cells
expressed higher levels of CD25 as compared to cells transduced
with the control retrovirus, although the MFI of CD25 was similar
between the two populations (Figure 3A). Both transduced
populations (M2 and M2.Stop) became surface IgG positive,
likely due to LPS stimulation coupled with retrovirus infection
selecting for the LPS-driven proliferating B cell population.
However, the M2 expressing B cells expressed higher levels of
surface sIgG than the control M2.Stop retrovirus transduced cells.
Similarly, the M2 and M2.Stop transduced populations both
upregulated CD138, although the presence of M2 did not lead to
the high levels of CD138 indicative of plasma cell differentiation.
Notably, the other changes observed in B cell differentiation were
unique to the M2-transduced B cell population versus the cells
transduced with the M2.Stop control retrovirus. In addition, the
M2-transduced B cells secreted significantly higher levels of IgG
on days 4–6 post-transduction than the cells transduced with the
control retrovirus (Figure 3B). Secreted IgM levels remained
similar throughout the time-course for M2 and control retrovirus
B cell cultures (Figure 3C). Importantly, M2-transduced cells
express surface IgG and remain CD138
low, indicating that they
have not fully differentiated into plasma cells. Together, these data
provide strong evidence that M2 expression leads to B cell
activation and differentiation similar to a functional activated, pre-
plasma memory B cell phenotype, namely CD19
+, sIgG
+, sIgD
2,
B220
low, CD138
low [33,34]. However, we cannot formally rule out
that M2 expression leads to differential survival and expansion of a
population of pre-plasma memory B cells present in the
transduced culture – although this seems unlikely based on the
Figure 2. M2 expression leads to enhanced survival and B cell proliferation. (A and B) M2-transduced cells have enhanced survival versus
the untransduced cells in culture as well as M2.Stop-transduced cells. Triplicate cultures were stained with Thy1.1-PE, 7-AAD, and AnnexinV-
PacificBlue and analyzed on a LSRII cytometer. (A) Representative data from 3 days post-transduction excluding obvious debris in the culture, gated
on Thy1.1 expression. (B) The percentage of live (AnnexinV
2 7-AAD
2) was determined from 2–6 days post-retroviral transduction with M2 or M2.Stop
in transduced (Thy1.1
+) and untransduced (Thy1.1
2) populations. Data is representative of two independent time-course experiments. (C and D) M2-
transduced B cells had enhanced proliferation early post-transduction. Triplicate B cell cultures were pulsed with 10 mM BrdU for 24 hours and
stained with Thy1.1-PE and BrdU-APC and analyzed on a FACScalibur. (C) Representative data from day 3 post-transduction shows M2-enhanced
proliferation of the transduced (Thy1.1
+) population, gated on viable cells. (D) Percent of transduced, proliferating cells over time demonstrates
enhanced proliferation in B cells transduced with M2 at days 3 and 4 post-transduction. Proliferation of the untransduced populations were similar
over the time-course. Statistical significance of the flow cytometry data was determined by two-tailed, unpaired Student’s T test with a confidence
level of 95%.
doi:10.1371/journal.ppat.1000039.g002
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B cells used for these studies.
M2 protein expression leads to secretion of IL-10
To further investigate the proliferative effects of M2 protein
expression in primary murine B cells, the supernatants of the
transduced B cells were screened for a variety of cytokines using a
mouse cytokine antibody array (see Materials and Methods).
Supernatants of B cell cultures transduced with M2 and control
retrovirus were compared at four days post-transduction
(Figure 4A). Cytokine arrays performed in duplicate time-course
experiments revealed substantial increases in IL-10, IL-2, IL-6,
and MIP-1a in the culture supernatants of B cells expressing M2
compared to the control retrovirus transduced B cell cultures
(Figure 4A). Cytokine levels throughout the time-course analyses
were subsequently quantitated by ELISA. IL-2 levels in the M2-
transduced cultures peaked at 50 pg/mL of supernatant at day 4
and waned by day 6 post-transduction, while only 1–2 pg/mL of
IL-2 were detected in the control retroviral supernatants
(Figure 4B). From 3 days post-transduction until the end of the
time-course, the supernatants from M2-expressing B cells
contained levels of IL-6 twice as high as those of B cells
transduced with the control retrovirus (780 pg/mL vs. 400 pg/
mL) at day 6 post-transduction (Figure 4C). There was also a 10-
fold increase in the level of MIP-1a with M2-transduced cultures
containing an average of 1845 pg/mL of MIP-1a versus 139 pg/
mL in the control retrovirus supernatant at the end of the time
course (Figure 4D). Notably, we observed a 20-fold increase in
IL-10 levels in the B cell cultures transduced with M2 with
17.5 ng/mL of IL-10 in the M2-transduced cultures as compared
to 0.9 ng/mL in the control retroviral supernatants at day 6 post-
transduction (Figure 4E). Notably, the number of cells in the M2
protein expressing and control B cell cultures were not
significantly different, and thus the observed differences in
cytokine levels cannot be explain by an increase in cell number.
These data demonstrate that M2 expression in primary murine B
Figure 3. M2 expressing cells have an activated, pre-plasma memory phenotype. (A) M2-transduced cells were CD19
+, CD25
high, GL7
high,
B220
low, I-A
bl o w , sIgD
2, sIgG
+, and CD138
low when compared to untransduced cells within the culture. Representative flow cytometry histograms at
day 4 post-transduction. The black line open histograms reflect staining of the transduced (Thy1.1
+) B cell population, while the filled gray histograms
reflect staining of the untransduced (Thy1.1
2) population. The top panels depict data from M2-transduced cultures; bottom panels depict data from
M2.Stop-transduced cells. Data is representative of three samples per time-point with at least three independent experiments per stain. (B and C)
ELISA quantitation of the levels of IgM and IgG in supernatants of M2 and M2.Stop transduced B cell cultures. Three samples were analyzed per time
point, and the data shown is representative of three independent experiments. Significance of differences in IgG secretion was determined by two-
tailed, unpaired Student’s T test with a confidence level of 95%. * p=0.0182, ** p=0.0352, *** p=0.0118.
doi:10.1371/journal.ppat.1000039.g003
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IL-10. Finally, to further assess the ability of M2 expression to up-
regulate IL-10 secretion from B cells, we transfected the murine
A20 B cell line with either a control expression vector (pIRES-
EGFP) or an M2 expression vector (pM2-IEGFP) and assessed IL-
10 secretion by ELISA (Figure 4F). Untreated A20 cells secrete
significant levels of IL-10, which were only modestly enhanced by
LPS treatment (Figure 4F). In addition, transfection of the control
expression vector had no impact of the levels of IL-10 secreted by
A20 cells (Figure 4F).However, transfection withtheM2 expression
vector lead to a substantial increase in the levels of IL-10 secretion
(Figure 4F). The latter result provides further evidence that M2 is
able to increase IL-10 secretion by B cells – independent of LPS
stimulation.
Figure 4. M2 expressing cells secrete more IL-2, IL-6, MIP-1a, and IL-10. (A) Cytokine antibody arrays were screened for the presence of
cytokines in the supernatants of M2 and M2.Stop transduced B cell cultures at day 4 post-transduction. Data is representative of supernatants from
two independent time-course experiments. (B–E) ELISAs of IL-2, IL-6, MIP-1a, and IL-10 levels in the culture supernatants M2 and M2.Stop transduced
B cells. Data shown from triplicate wells analyzed from a single time-course analysis. The data shown are representative of three independent
experiments. (F) IL-10 ELISAs of culture supernatants from the murine A20 cell line, either transfected with an empty plasmid (pBluescript II SK) and
untreated, treated with LPS, or following transfection with a control expression plasmid (pIRES-EGFP) or an M2 expression plasmid (pM2-IEGFP). The
difference between the levels of IL-10 in the culture media of vector control and M2 expression vector transfected A20 cells was statistically
significant (p=0.0054).
doi:10.1371/journal.ppat.1000039.g004
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IL-10 has been demonstrated to be involved in the establish-
ment of a latent MHV68 infection, and we asked whether IL-10
played a role in M2-driven B cell proliferation [35,36]. To address
the role of IL-10 in M2-driven proliferation, B cells were isolated
from wild-type and IL-10
2/2 mice, transduced with M2 or the
control retrovirus, and surface Thy1.1
+ expression was monitored
over a six day time course. Although the percentage of M2-
transduced C57Bl/6 B cells increased from 40% to 85% of the
culture, as previously observed (see Figure 1C), there was only a
modest expansion of the Thy 1.1
+ population from 37% to 49% in
the IL-10
2/2 cultures transduced with M2 expressing MSCV
retrovirus (Figure 5A). ELISAs of the supernatants from the
transduced cultures confirmed that the IL-10
2/2 B cells do not
secrete detectable levels of IL-10 (Figure 5B). We noted an
approximately 10% increase in the percentage of IL-10
2/2 M2
protein expressing B cells over the time course experiments, and
we hypothesize that this small increase might be due to the ability
of the M2 protein to manipulate proliferation and/or survival
pathways independent of IL-10. Notably, IL-10
2/2 mice have
been shown to have 20-fold higher levels of serum IL-6 than IL-
10-sufficient mice [37], and indeed we observed a two-fold
increase in IL-6 in the IL-10
2/2 B cell supernatants of the
untransduced population at day 2 (Figure 5C). Expression of the
M2 protein led to a four-fold increase in the levels of IL-6 in the
culture supernatants of IL-10
2/2 B cells (Figure 5C). In addition,
MIP-1a levels were four-fold higher in the IL-10
2/2 B cell
cultures at day 2 post-transduction, and this increase was observed
throughout the time-course (data not shown). However, the
increased levels of IL-6 and MIP-1a observed in the M2-
transduced IL-10
2/2 cultures could not compliment the loss of
IL-10 in the cultures, leading us to hypothesize that IL-10
secretion is required for the expansion of the M2 protein-
expressing B cells.
To more directly assess the role of IL-10 in M2 protein-
mediated B cell proliferation and survival, we tested the ability of
the cytokine enriched supernatants from transduced wild-type and
IL-10
2/2 B cells to compliment loss of M2 and IL-10 expression
in culture. After analysis of transduction efficiency at two days
post-transduction, one third of the supernatant from the WT
MSCV-M2.Stop and IL-10
2/2 MSCV-M2 transduced cultures
was replaced with an equal volume of supernatant from C57BL6
MSCV-M2 cultures from the respective days post-transduction. B
cells were analyzed for Thy1.1 expression for the remainder of the
time-course, and IL-10 levels were measured by ELISA (data not
shown). Interestingly, addition of culture supernatants from
C57BL6 M2 protein expressing B cells to C57BL6 B cells
transduced with MSCV-M2.Stop failed to induce significant
proliferation of the transduced B cells (Figure 5D). In contrast,
addition of IL-10 containing culture supernatants to IL-10
2/2 B
cells expressing the M2 protein led to a steady proliferation nearly
equivalent to that of C57BL6 B cell cultures expressing the M2
protein (Figure 5D).
Finally, to formally demonstrate that IL-10 is required for the
observed phenotype, we transduced IL10
2/2 B cells with either
the M2 or M2.Stop control recombinant MSCV viruses and
assayed the frequency of Thy 1.1. cells in the culture over time in
the presence and absence of recombinant IL-10 (Figure 5E). As
expected, the addition of recombinant IL-10 had no discernable
effect on M2 expressing IL-10-sufficient B cells recovered from
C57Bl/6 mice. However, addition of IL-10 to the M2 transduced
IL-10
2/2 B cells (but not the M2.Stop transduced IL-10
2/2 B
cells) rescued the dominance phenotype (Figure 5E). These results
demonstrate that both intracellular M2 expression and IL-10
secretion are necessary for the observed proliferative expansion of
the transduced B cell population, and that neither one alone is
sufficient to induce this expansion. These data suggest that M2
manipulates intracellular signaling pathways which enhance the
response to IL-10 signaling as well as induce IL-10 secretion.
Loss of M2 protein expression during MHV68 infection
results in a significant reduction in serum IL-10 levels
Previous studies have shown that in the absence of a functional
M2 gene, establishment of MHV68 latency following intranasal
inoculation is severely reduced [24]. Similarly, inoculation of IL-
10
2/2 mice with wild-type MHV68 leads to a decrease in the
establishment of latency [35,36]. To determine whether M2
expression leads to IL-10 secretion in vivo, C57Bl/6 mice were
infected (either 1,000 pfu via intranasal inoculation or 100 pfu via
intraperitoneal inoculation) with either a recombinant MHV68
harboring the same translation termination codon near the 59 end
of the M2 open reading frame as used in control retrovirus
construction (MHV68/M2.Stop) or with a genetically repaired
marker rescue isolate of the same locus (MHV68/M2.MR). Both
intranasal and intraperitoneal inoculation of the M2-null mutant
were assessed, since we have previously reported that route of
inoculation impacts the latency phenotype observed [24]. Serum
IL-10 was measured by in vivo cytokine capture and ELISA
(Figure 6, panels A & B). Notably, mice infected with MHV68/
M2.Stop had serum IL-10 levels that were only slightly elevated
over the levels present in naı ¨ve mice and were 2- to 3-fold lower
than the levels observed in mice infected with the marker rescue
virus (MHV68/M2.MR). Notably, this phenotype was indepen-
dent of the route of inoculation (Figure 6, panels A & B). As we
have previously reported [24], we observed defects in both
establishment of latency (which was accentuated following
intranasal inoculation), as well as reactivation from latency with
the M2-null mutant MHV68 (Figure 6, panels C & D).
Intraperitoneal infection with MHV68/M2.Stop increased the
establishment of latency eight-fold over intranasal inoculation, yet
serum IL-10 levels were very similar to those observed following
intranasal inoculation (Figure 6). Importantly, the serum levels of
IL-10 we observed in MHV68/M2.MR infected mice were similar
to those previously observed [35]. These results provide strong
evidence that M2 induction of IL-10 secretion, either from latently
infected B cells or some other latency reservoir (e.g., infected
macrophages or dendritic cells), contributes significantly to the
serum levels of IL-10 observed during MHV68 infection following
either intranasal or intraperitoneal virus inoculation.
Loss of M2 expression during MHV68 infection correlates
with an increase in virus-specific, activated CD8
+ T cells
We next examined whether loss of M2 expression and the
concomitant reduction in IL-10 expression might alter the CD8 T
cell response to MHV68 since IL-10 is known to suppress T cell
responses [18]. Thus, we examined the MHV68-specific CD8
+ T
cell response following infection of mice with either MHV68/
M2.Stop or MHV68/M2.MR. Mice were infected intraperitone-
ally with 100 pfu of MHV68/M2.Stop or MHV68/M2.MR and
splenocytes were harvested at day 16 post-infection, a time at
which lytic virus has been cleared and latency established. As
previously reported, there was a ten-fold decrease in establishment
of latency with a 20-fold decrease in reactivation (Figure 6D).
Splenocytes from individual mice were stained for activated,
tetramer positive CD8
+ T cells using tetramers specific to two
MHV68 antigens encoded by ORF6 and ORF61 (Figures 7,
panels A–C). Both tetramers used in this analysis were specific for
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two independent experiments, tetramer staining for two different
lytic antigens revealed a statistically significant increase in the
frequency of tetramer-specific, activated CD8
+ T cells in mice
infected with MHV68/M2.Stop compared to MHV68/M2.MR
(Figure 7A–C). In contrast, there was no global change in overall
CD8 activation as determined by the percentage of CD8
+
CD11a
high T cells in the spleens of infected mice (Figure 7D).
CD4
+ T cell activation, as well as the percentage of CD44
high
CD62L
low CD4
+ and CD8
+ T cells, was the same in the two
groups of infected mice (data not shown). These data indicate that
the loss of M2 during MHV68 infection specifically enhanced the
MHV68-specific CD8
+ T cell response, despite a significant
decrease in viral latency and reactivation (see Figure 6D).
Figure 5. M2 expressing B cells fail to expand in the absence of IL-10. (A) B cells from C57Bl6 and IL-10
2/2 mice were isolated from
splenocytes and transduced with either the M2 or M2.Stop retroviruses. Triplicate wells were analyzed per time-point. IL-10
2/2 B cells transduced
with M2 failed to expand to the same extent as wild-type B cells. Data shown are representative of 3 independent experiments. (B) Quantitative ELISA
analyses confirm that IL-10
2/2 B cells fail to secrete IL-10. (C) IL-10
2/2 B cells transduced with M2 secrete significantly higher levels of IL-6 than C57Bl/
6 B cells transduced with M2. However, IL-6 fails to compensate for the IL-10 deficiency. Data shown is representative of two independent
experiments, each containing triplicate cultures. (D) Supernatants from C57Bl6 B cells transduced with M2 compliment for the IL-10
2/2 B cell
proliferation defect. B cells from C57Bl6 and IL-10
2/2 mice were isolated and triplicate cultures transduced with M2 or M2.Stop retroviruses. On day 2
post-transduction, 500 mL of supernatant from the C57Bl6 B cells transduced with the M2.Stop retrovirus and IL-10
2/2 B cells transduced with the M2
retrovirus were replaced with 500 mL of tissue culture supernatant recovered from the C57Bl6/M2 B cell cultures from that respective day. Triplicate
wells were analyzed per time-point. High IL-10 levels fail to complement the lack of M2 expression in the C57Bl/6 B cells, but did drive proliferation of
the M2-transduced IL-10
2/2 B cells. Data are represented as the fold-change in percent Thy1.1 positive cells in the cultures over the percent Thy1.1
positive cells present at two days post-transduction. (E) Recombinant murine IL-10 rescues M2-mediated expansion of IL-10
2/2 B cells, but fails to
expand either the C57Bl/6 or IL-10
2/2 M2.Stop transduced B cell populations. B cells from C57Bl6 and IL-10
2/2 mice were isolated from splenocytes
and transduced with either the M2 or M2.Stop retroviruses. IL-10 was added (final concentration of 20 ng/ml) to the indicated samples starting on
day 2 post-transduction (see text for description). Triplicate wells were analyzed per time-point.
doi:10.1371/journal.ppat.1000039.g005
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expression during infection is unique in that the MHV68-specific
T cell response is increased correlating with a decrease in serum
IL-10 levels. These data point to a potential role of M2 protein-
mediated IL-10 secretion in the quiescence of the virus-specific T
cell response in vivo which may facilitate both the efficient
establishment of latency as well as reactivation from latency.
Discussion
The latency-associated M2 protein is critical for establishing
splenic latency following low dose intranasal inoculation and for
virus reactivation from latency following low dose intraperitoneal
inoculation [23,24]. In the absence of M2, infected B cells are
unable to efficiently transition from the germinal center to the
follicles [26]. Early in latency, there is an accumulation of latently
infected naı ¨ve B cells in the absence of the M2 protein, indicating
a role for the M2 protein in manipulating B cell development
during infection [24]. Epstein-Barr virus is hypothesized to drive
naı ¨ve B cells to enter the germinal center reaction in order to
establish latency in the memory B cell pool [7,38,39]. In long-
term EBV carriers, lytic EBV gene transcripts are preferentially
found in the plasma cell population, leading to a model whereby
reactivation from latency is associated with differentiation from
memory to plasma cell [40]. B cell proliferation is necessary for
the establishment of MHV68 latency, and, similar to EBV,
memory B cells are the primary long-term latency reservoir
[8,9,30]. Reactivation is hypothesized to be needed for efficient
seeding of the spleen during the establishment phase of MHV68
infection, and, as such, the M2-associated defects in establishment
Figure 6. Loss of M2 expression in vivo correlates with reduced serum IL-10 at the onset of latency. The reduction in serum IL-10 is
independent of the route of infection and correlates with a significant reduction in reactivation from latency in the absence of M2. Groups of four to
five mice were infected with 1000 pfu of M2 null mutant (MHV68/M2.Stop) or the M2 marker rescue virus (MHV68/M2.MR) via intranasal inoculation
or 100 pfu via intraperitoneal inoculation (or naı ¨ve mice). On days 14 or 15 post-infection, mice were injected with biotin labeled anti-IL-10 antibody
i.p. Twenty-four hours later, serum was collected for analysis of IL-10 levels (A and B), and splenocytes were recovered for determinations of the
frequency of viral latency and reactivation (C and D). Data shown for intranasal inoculations is representative of two independent experiments, 4–5
mice per group, with IL-10 levels measured in individual mice and splenocytes pooled for viral latency assays (as described in Materials and Methods).
Data shown for intraperitoneal inoculations is representative of three independent experiments, 4–5 mice per group, with IL-10 levels measured in
individual mice and splenocytes pooled for viral latency assays. (A and B) Total serum IL-10 levels were significantly lower in mice infected with
MHV68/M2.Stop compared to MHV68/M2.MR virus, independent of the route of infection. Intranasal infection data is from 10 individual mice from
two independent infections; intraperitoneal data is from 15 individual mice from three independent infections. Two naı ¨ve animals were analyzed per
infection * p=0.0117, ** p=0.0005. Significance of IL-10 data was determined by two-tailed, unpaired Student’s T test with a confidence level of 95%.
(C and D) Frequencies of splenocytes from MHV68/M2.MR and MHV68/M2.Stop infected mice harboring latent viral genomes and reactivating from
latency upon explant. The frequency of latency was determined by nested, limiting-dilution PCR (LD-PCR) as previously described [3]. The frequency
of cells reactivating from latency upon in vitro culture was determined by plating serial dilutions of live, intact splenocytes on mouse embryonic
fibroblast monolayers and scoring cytopathic effect 14–21 days post-explant, as previously described [3]. Data from both assays was subjected to
nonlinear regression analysis with a sigmoidal dose-response algorithm for best fit. Data points represent individual experiments with splenocytes
pooled from 4–5 mice per condition.
doi:10.1371/journal.ppat.1000039.g006
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functionally linked. In this study we explored the impact of M2
protein expression in primary murine B cells - a system capable of
differentiation.
M2 expression in primary B cells led to proliferation of
transduced B cells, driving a rapid expansion of transduced cells
within the culture, regardless of initial transduction efficiency.
Although both the transduced (Thy1.1
+) and untransduced
(Thy1.1
2) B cell populations could be shown to be proliferating
(by BrdU incorporation), the enhanced proliferation and survival
of the M2-transduced B cells rapidly led to this population
dominating the mixed culture. In primary murine B cells, M2-
driven proliferation was dependent on the B cell’s ability to secrete
IL-10 and respond to IL-10 signaling. Notably, transfer of culture
supernatants from M2 expressing C57Bl/6 B cells, or addition of
recombinant murine IL-10, did not result in dominance of the
M2.Stop retrovirus transduced (i.e., Thy1.1
+) population in the
absence of M2 protein expression, leading us to hypothesize that
some other function(s) of the M2 protein augments IL-10
signaling. Culturing stimulated human memory B cells with IL-
10 or IL-2 and IL-6 leads to plasma cell differentiation [41,42].
Also, an increase in MIP-1a transcription is associated with
differentiation to a plasma cell phenotype [43]. Human germinal
center B cells can be induced to differentiate into plasma cells
rather than memory B cells in the presence of IL-10 [44]. In
contrast to human B cells, IL-10 enhances murine B cell viability
but does not drive proliferation [19]. Our data suggest that the
MHV68 M2 protein uniquely increases the murine B cell
proliferative response to IL-10, mimicking the role of IL-10
signaling in human B cells.
Figure 7. Loss of M2 protein expression and reduction of serum IL-10 levels correlates with an enhancement in the MHV68-specific
tetramer response. Groups of four to five mice were infected with 100 pfu via intraperitoneal inoculation with either MHV68/M2.Stop or MHV68/
M2.MR. Sixteen days post-infection, at the onset of latency, splenocytes were analyzed by flow cytometry. (A) Splenocytes were stained with
tetramers for two MHV68 lytic antigens, ORF6487-498/D
b-APC or ORF61524-531/K
b-APC, anti-CD8-PacificBlue, and anti-CD44-FITC. The data shown is
from mice with an intermediate phenotype representative of the median in each group. (B and C) Mean percentage of ORF6-specific (panel B) and
ORF61-specific (panel C) T cells was significantly higher in the absence of the M2 protein (* p,0.0001, ** p=0.0009). Tetramer data was compiled
from the analysis of individual mice and represents two independent infections with 5 mice per group per infection. (D) Mean percentage of
activated CD8
+ T cells did not significantly change in the absence of the M2 protein. Data shown is from one representative set of infections of five
mice from three independent experiments. Statistical significance of the flow cytometry data was determined by two-tailed, unpaired Student’s T test
with a confidence level of 95%.
doi:10.1371/journal.ppat.1000039.g007
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retained surface expression of CD19 and IgG, and remained
CD138
low, indicating that they did not fully differentiated into
plasma cells. Instead, the surface phenotype of the B cells
expressing M2 most closely resembled that of a pre-plasma
memory B cell, an intermediate stage in development between
the memory and plasma cell phenotypes [33,45]. Together, this
data supports a model wherein infection of naı ¨ve B cells in the
lung with MHV68 leads to M2 expression, B cell proliferation
and activation, and differentiation to a pre-plasma memory B cell
phenotype. Depending on other cytokines and signals in the area,
M2-expressing B cells may further differentiate into memory B
cells, establishing long-term latency, or plasma B cells, potenti-
ating virus reactivation. Thus, in this model of MHV68
pathogenesis, M2 protein manipulation of B cell differentiation
to an intermediate pre-plasma memory B cell phenotype could
facilitate both virus reactivation as well as establishment of viral
latency.
IL-10 has potent immunoregulatory activity, suppressing
proinflammatory cytokine secretion and activation of antigen-
presenting cells - functions which result in suppressed NK cell and
T cell activity [46]. IL-10 plays an important role in MHV68
pathogenesis, but prior to our analyses of M2 protein function no
specific viral antigen had previously been shown to stimulate
cellular IL-10 production. It has been shown that ex vivo
stimulation of MHV68 latently infected splenocytes with
MHV68-infected antigen presenting cells resulted in IL-10
secretion peaking at the onset of splenic latency, and B cells were
shown to be responsible for a significant portion of the IL-10
secreted [47]. Dendritic cells isolated from MHV68 infected mice
express IL-10 transcripts, and dendritic cells infected ex vivo
secrete IL-10 only when concurrently stimulated with LPS [36].
Interestingly, these investigators showed that M2 is transcribed by
infected dendritic cells, although they did not demonstrate that IL-
10 secretion was mediated by M2 [36]. In the absence of IL-10,
establishment of MHV68 latency is decreased concurrent with an
increase in serum IL-12 p70 and splenomegaly, demonstrating a
role for IL-10 in both establishment of latency as well as
immunosuppression [1,35,47].
We observed a significant decrease in serum IL-10 in mice
infected with an M2-null MHV68 mutant. Notably, the decreased
serum IL-10 levels correlated with an increase in the percentage of
MHV68-specific CD8
+ T cells. Furthermore, it is important to
note that this increased CD8+ T cell response was in the setting of
an infection where virus reactivation was severely attenuated.
Therefore, increased persistent virus replication cannot explain the
increase in the tetramer-specific response. Thus, we hypothesize
that during M2-mediated reactivation there is concurrent IL-10
secretion, locally dampening the ability of the MHV68-specific
CD8
+ T cells to clear the infected cells, leading to enhanced
establishment and reactivation from latency.
Manipulation of the IL-10 signaling pathway appears to be a
conserved mechanism used by a number of herpesviruses. EBV
encodes a viral IL-10 homolog, BCRF1 (or vIL-10), that has been
shown to increase human B cell proliferation following surface
immunoglobulin crosslinkinking and induce B cells to secrete
increased levels of IgM, IgG, and IgA in a similar manner to
cellular IL-10 [17]. In the absence of vIL-10, EBV can still
efficiently establish latent, long-term lymphoblastoid lines (LCLs)
[48]. Exogenous vIL-10 added during the transformation of B cells
by EBV enhanced both the rate and frequency of growth
transformation, and antisense oligonucleotides to vIL-10 could
negate this enhancement [49,50]. Human IL-10 could comple-
ment the loss of vIL-10 during EBV infection of B cells,
demonstrating that it is IL-10 mediated signaling that augments
B cell transformation following EBV infection [50]. LMP1, a
functional CD40 ortholog encoded by EBV, is both IL-10
responsive and induces secretion of cellular IL-10 in stimulated
Burkitt’s lymphoma cells [51,52]. Patients with EBV-associated
post-transplant lymphoproliferative disease also have elevated
serum IL-10, but not IL-6 [53]. However, in vivo, whether the
primary role of vIL-10 is to suppress the immune response, trigger
B cell proliferation and differentiation or both is unclear. Serum
cellular IL-10 levels are elevated both during primary EBV
infection as well as during EBV reactivation from latency,
implying that IL-10 plays a role in both the establishment and
reactivation from latency [54].
Human cytomegalovirus (HCMV), a beta herpesvirus, en-
codes a viral IL-10 (cmvIL-10) that has only 27% homology to
cellular IL-10, but is nevertheless capable of binding the IL-10
receptor and mediating downstream STAT1/STAT3 signaling
[55]. Human cmvIL-10 is capable of downregulating MHC I
and II, suppressing PBMC proliferation, and decreasing IFNc,
IL-1a, GM-CSF, IL-6, and TNF-a secretion in response to
stimulation [56]. Transcripts encoding cmvIL-10 have been
d e t e c t e di nt h eb o n em a r r o wa n dm o b i l i z e dp e r i p h e r a lb l o o d
during natural HCMV latency, indicating that cmvIL-10 may
play a role in either establishment, maintenance, or reactivation
from latency [57]. Murine CMV (MCMV) does not encode an
IL-10 homolog, although, parallel to the studies of Flano et al. on
dendritic cells infected with MHV68 [36] , in vitro MCMV
infection of primary macrophages results in secretion of cellular
IL-10 and downregulation of MHC II [58]. Recently, IL-10
production by CD4 T cells has been shown to be of key
importance in regulating MCMV persistence in the salivary
glands. Blockade of the IL-10R resulted in a significant decrease
in the titer of MCMV in the salivary glands with a concurrent
increase in the frequency of IFNc-producing CD4 T cells,
indicating a role for IL-10 in the maintenance of a MCMV
infection, possibly through reactivation from latency [59]. It
seems reasonable to speculate that suppression of the host
response may help these viruses both establish latency as well as
reactivate from latency, reseeding the latency reservoir without
clearance by memory T cell responses.
IL-10 has been implicated in the pathogenesis of both
autoimmune as well as viral diseases, and the fact that many
viruses carry IL-10 orthologs speaks to the potency of IL-10 in
manipulating the host immune system [60,61]. The parapoxvirus,
ORF virus, encodes a viral IL-10 homolog with 80% homology to
ovine IL-10 and is capable of inhibiting T cell proliferation [62].
Finally, two independent reports have demonstrated that blockade
of the IL-10 receptor during chronic lymphocytic choriomeningitis
virus infection led to clearance of the infection with enhanced IL-
10 production by dendritic cells [63,64].
We also observed a significant increase in IL-6 and MIP-1a in
the B cell cultures transduced with M2. Interestingly, KSHV
encodes homologs of both IL-6 and MIP-1a, suggesting that these
cytokines have key roles in gammaherpesvirus immunomodulation
that we have yet to appreciate [16]. MIP-1a can be detected in the
BAL and lung homogenate of MHV68-infected mice at the peak
of lytic replication, but the contribution of this cytokine to latency
and reactivation has not been studied directly [65,66]. During
MHV68 infection, MIP-1a secretion in the lungs may attract B
cells to the area of acute replication, facilitating viral infection and
trafficking to the spleen. There is no significant difference in
pathology or viral latency in IL-6
2/2 mice, despite the fact that
upon ex vivo stimulation infected splenocytes secrete IL-6 [67].
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these cytokines.
Does M2-driven IL-10 secretion play a critical role in MHV68
latency? The studies presented here provide an indication that the
M2 protein has multiple functions – some of which are necessary
for primary murine B cells to respond to IL-10 signaling in the
retroviral transduction assays we have described. Our attempts to
neutralize IL-10 in the B cell culture system have been
unsatisfactory (data not shown) – perhaps owing to the difficulty
of neutralizing the autocrine activity of IL-10 expressed from
primary murine B cells. Thus, we anticipate that attempting to
neutralize IL-10 in vivo during MHV68 infection will be difficult.
As a distinct approach, we have recently published the analysis of a
panel of point mutations in candidate functional motifs in the M2
protein [68]. The latter studies have also provided evidence for the
presence of multiple functionally important domains in M2 [68].
With respect to M2-driven B cell proliferation and IL-10 secretion,
we analyzed in primary B cells three M2 mutants which, in the
context of virus infection, were severely attenuated in establish-
ment and reactivation from MHV68 latency. Notably, two of
these mutations (Y129F/P7 and P8) ablated the IL-10 dependent
proliferative dominance phenotype in primary B cell cultures while
the other mutation (P9) was similar to wild type M2 [68]. The
latter result underscores that M2 is a multifunctional protein. In
addition, these studies link M2 functional domains that play a
critical role in MHV68 latency in vivo to M2-driven IL-10
secretion. Further studies will be required to assess the contribu-
tion of M2-driven IL-10 expression to chronic MHV68 infection.
In summary, the analysis of M2 protein function provides a
unique insight into an immunomodulatory mechanism that is
employed by many viruses, particularly the herpesvirus family. Our
work demonstrates that the M2 protein, a unique viral protein,
manipulates B cell signaling to induce cellular IL-10 secretion and
make cells more responsive to IL-10 signaling, leading to
proliferation and enhanced survival of M2-expressing primary B
cells in culture. M2 expression in primary murine B cells results in
differentiation to a pre-plasma memory B cell phenotype, an
intermediate in mature B cell development. In addition, M2 protein
expression correlates with high serum IL-10 levels and an increased
frequency of virus-specific CD8
+ T cells during MHV68 infection.
We conclude that driving B cell proliferation, survival and
differentiation, while simultaneously dampening the host immune
response to the virus, is an elegant immunomodulatory mechanism
used by MHV68 to both facilitate establishment of latency and
subsequent episodic virus reactivation from latency.
Methods
Mice and infections
Female C57Bl/6 and IL-10
2/2 mice 6 to 8 weeks of age were
purchased from the Jackson Laboratory. Mice were sterile housed
and treated according to the guidelines at Emory University
School of Medicine (Atlanta, GA). Following sedation, mice were
infected intranasally with 1000 pfu of either MHV68/M2.Stop or
MHV68/M2.MR in 20 mL of cMEM. Mice were infected with
100 pfu of MHV68/M2.Stop or MHV68/M2.MR in 500 mLo f
cMEM intraperitoneally. Mice were allowed to recover from
anesthesia before being returned to their cages.
B cell isolation
Spleens were homogenized and erythrocytes removed by
hypotonic lysis. B cells were enriched using negative selection by
magnetic cell separation with the mouse B Cell Isolation Kit
(Miltenyi Biotech). Purity was confirmed by staining for CD19, and
B cells used in experiments were 93–97% pure. Cells were cultured
in RPMI-1640 supplemented with 10% FCS, 100 U/mL penicillin,
100 mg/mL streptomycin, 2 mM L-glutamine, 10 mM HEPES,
1 mM sodium pyruvate, 10 mM non-essential amino acids, and
25 mg/mL of LPS (Sigma) overnight before retroviral transduction.
Cloning, retroviral production, and transduction
BglII sites were cloned flanking the M2 ORF with primers 59
CAG CTC AGA TCT ATG GCC CCA ACA CCC 39 and 59
CAG CTC AGA TCT TTA CTC CTC GCC CCA 39 and
cloned into pCR-Blunt (Invitrogen). Positive clones were se-
quenced, digested with BglII, and cloned into the pMSCV-IRES-
Thy1.1 vector (a gift from Philippa Marrack) to construct
pMSCV-M2-IRES-Thy1.1. pMSCV-M2Stop-IRES-Thy1.1 was
constructed in a similar manner. Retroviruses were produced
using the BOSC23 producer cell line (ATCC). 2610
6 BOSC23
cells were plated on 60 mM Collagen II coated plates. The
following day, 10 ug of pMSCV vector was transfected into the
BOSC23 cells using the LT-293T reagent from Mirus Biotech.
Retroviral supernatants were harvested 48 to 72 hours post-
transfection, centrifuged at 2000 rpm for 10 minutes to clear cell
debris, and supplemented with 5 mg/mL of polybrene. B cells
were transduced by removing 700 mL of media and replacing it
with 1 mL of retroviral supernatant/polybrene. Cells were spun at
2500 rpm at 30uC for one hour. 750 uL of retroviral supernatant
was removed and replaced with fresh, complete RPMI. Cells were
rested for 48 hours before analysis.
In some analyses recombinant IL-10 was added back to
transduced primary B cell cultures, as follows. Primary murine B
cells were harvested from C57Bl6 and IL-10
2/2 mice as
previously described. Transduction efficiencies were measured
48 hours post-transduction by flow cytometry. Following day 2
analysis, indicated cultures received 20 ng/mL of murine
recombinant IL-10 (Peprotech). B cell populations were analyzed
on days 3–5 post-transduction by flow cytometry.
Immunoprecipitations and western blotting
Cells were lysed in a suitable volume of ELB buffer on ice for
20 minutes. Lysates were pre-cleared with pre-immune chicken
IgY, and M2 precipitated with chicken anti-M2 IgY followed by
capture by agarose anti-IgY beads (Aves Labs, Inc.). Precipitates
were run on a 15% acrylamide gel, transferred to nitrocellulose
membranes, and blotted with rabbit anti-M2 antisera followed by
donkey anti-rabbit HRP. Protein was detected using chemilumi-
nescence on Kodak X-Omat Blue XB-1 film.
Flow cytometry
Rat anti-mouse CD16/32 (Fc block) was used prior to staining
in most experiments. Cells were stained with the following
antibodies: Thy1.1-FITC, -PE, or –APC (eBiosciences), CD44-
FITC (Caltag), CD62L-PE (Caltag), GL7-FITC, IgG1, 2a, 2b, 3-
FITC, CD25-PE, CD138-PE, I-A
b-PE, CD4-PerCP, CD11a-PE-
Cy7, CD19-APC, B220-APC, CD8-PacficBlue (BD Pharmigen
except where noted). Tetramers were synthesized at the NIH
Tetramer Core Facility at Emory University and conjugated to
streptavidin-APC (Molecular Probes) according to core protocol.
Intracellular bromodeoxyuradine incorporation was measured
using BrdU-APC according to the manufacturer’s protocol (BD
Pharmigen). AnnexinV-PacificBlue and 7-AAD reagents were
purchased in the VybrantH Apoptosis Assay Kit #14 (V35124)
from Molecular Probes and used per manufacturer’s protocol.
Cells were analyzed on FACScalibur or LSR II flow cytometer.
Data was analyzed using FlowJo software (TreeStar, Inc., San
Carols, CA).
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assays (ELISAs)
TranSignal
TM Mouse Cytokine Antibody Arrays 1.0 (Pa-
nomics, Inc.) were used to screen for secreted cytokines as per
manufacturer’s instructions. Membranes were blocked in
Blocking Buffer for two hours, washed, and then incubated for
two hours at room temperature with day four supernatants from
B cells transduced with MSCV-M2 or MSCV-M2.Stop.
Membranes were washed and incubated with Biotin Conjugated
Anti-Cytokine Mix as per protocol. Membranes were washed
and incubated with Streptavidin-HRP. After a final wash,
bound cytokine was detected using chemiluminescence on
K o d a kX - O m a tB l u eX B - 1f i l m .C y t o k i n e sw e r eq u a n t i t a t e d
by ELISA. IL-6 and IL-10 were detected with reagents from BD
Biosciences, and IL-2 and MIP-1a were detected with reagents
from R&D Biosystems. IgM and IgG were detected with
reagents from Bethyl Biosciences.
Transfection of murine A20 cell line
Triplicate cultures of 1610
6 A20 B cells were nucleofected
(Amaxa Biosystems) with 4 ug of pIRES2-EGFP (BD Biosciences
Clontech), pM2-IRES-EGFP [68], or pBluescriptIISK (Strata-
gene) using Solution T with setting T-01 on an Amaxa
Nucleofector I (Amaxa Biosystems). Cells transduced with
pBluescriptIISK were stimulated with 100 ng/mL of LPS
following nucleofection as indicated. 48 hours post-nucleofection,
supernatants were harvested and secreted IL-10 measured by
ELISA (BD Biosciences).
MHV68 viral mutagenesis
A MHV68 genomic fragment containing the region from bp
2403 to bp 6262 (WUMS sequence) [69] was cloned into the
Litmus-38 plasmid (Lit38-M2) as previously described [23]. With
Lit38-M2 as a template, a stop codon was introduced into the M2
ORF using the following oligonucleotides: Oligo1 (59 CCA CCA
GGC CGA AGC TTA CGG ATT GGG AAT C) and Oligo2 (59
CCA ATC CGT AAG CTT CGG CCT GGT GGA TG)
generating a translational stop codon at bp 4566 and introducing a
Hind III restriction site. The resultant product was ligated into the
pCR Blunt plasmid (Invitrogen). In addition, an M2 marker rescue
pCR Blunt plasmid was generated by PCR using Lit38-M2 as a
template and designated as M2.MR. M2.Stop pCR Blunt plasmid
and M2.MR were sequenced to verify the introduction of the site
directed point mutations and the absence of unwanted mutations.
Recombinant viruses were generated by allelic exchange in E. coli,
as described by Smith and Enquist [70,71]. Briefly, the Not I and
Bam HI restriction sites within pCR Blunt were used to liberate the
MHV68 genomic region contained within the plasmid. This
fragment was cloned into the suicide vector pGS284 which
harbors an ampicillin gene and a levansucrase cassette for positive
and negative selection, respectively. The resulting plasmid was
transformed into S17lpir E. coli cells and mated to GS500 E. coli
(RecA
+) containing wt MHV68 BAC. Cointegrants were selected
on Luria-Bertani (LB) agar plates containing chloramphenicol
(Cam) and ampicillin (Amp) and were resolved following overnight
growth in LB medium with Cam. Next, bacteria were plated on
LB agar plates containing Cam and 7% sucrose to select for loss of
pGS284 vector sequence. Individual colonies harboring site
specific point mutations within M2 were identified by colony
PCR followed by restriction digest. Positive clones were grown in
LB medium with Cam, and BAC DNA was purified with a Midi
Prep Kit (Qiagen, Hilden, Germany) as described by the modified
manufacturer’s protocol. The presence of site specific point
mutations and the absence of unwanted mutations within the
region of homologous recombination were confirmed by sequenc-
ing and southern blot. Virus stocks were generated by Superfect
(Qiagen, Hilden, Germany) transfection of recombinant MHV68
BAC DNA into Vero-Cre cells as previously described [70]. In
wells showing cytopathic effect (CPE), virus was harvested, cleared
of cell debris, and used to infect Vero-Cre cells in order to generate
high-titer stocks. Following the presence of CPE in Vero-Cre cells,
samples were harvested, homogenized, clarified, and aliquoted for
storage at 280uC. Virus stock titers were determined by plaque
assay as previously described [23,72].
MHV68 viral assays
Limiting dilution assays for frequency of latent were
performed as previously described [23,24]. To determine the
frequency of cells harboring latent viral genomes, single-copy-
sensitive nested PCR was performed. Frozen samples were
thawed, washed in isotonic buffer, counted, and plated in three-
fold serial dilutions in a background of 10
4 NIH 3T12 cells in 96
well plates. Cells were lysed by protease K digestion for six
hours at 56uC. Two rounds of nested PCR were performed per
sample with twelve samples per dilution, and the products were
resolved on 2% agarose gels. In order to measure the frequency
of reactivating splenocytes, bulk splenocytes were resuspended
in cMEM and plated in serial two-fold dilutions on mouse
embryonic fibroblast (MEF) monolayers in 96-well tissue culture
plates. Parallel samples of mechanically disrupted cells were
plated to detect preformed infectious virus. Wells were scored
for cytopathic effect 14 to 21 days post-explant.
In vivo cytokine capture assay
The Mouse IL-10 In Vivo Capture Assay Set (BD Biosciences)
was used to detect IL-10 in vivo during infections. On day 14–
15 p.i., parallel groups of five mice were injected with 10 mgo f
biotinylated rat anti-mouse IL-10 antibody in 200 ml of sterile
PBS. Mice were bled on day 15–16 p.i. and serum collected.
Samples were prepared and assayed by ELISA as per protocol.
The limit of detection of this assay is 31.3 pg IL-10/mL of serum.
Statistical analysis
Data analysis was conducted using GraphPad Prism software.
Error bars in all graphs depict standard error of the mean. For
limiting-dilution analysis, data was subjected to nonlinear
regression analysis with a sigmoidal dose-response algorithm for
best-fit. Poisson distribution predicts that the frequency at which
63.2% of wells are positive for an event (PCR or reactivation) is the
frequency at which there is at least one event present in the
population. Statistical significance of the flow cytometry and
ELISA data was determined by two-tailed, unpaired Student’s T
test with a confidence level of 95%.
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